What Sexually Transmitted Diseases Does Clindamycin Treat?

Clindamycin is used to treat bacterial vaginosis and, in combination with other antibiotics, pelvic inflammatory disease. Those are the two sexually associated conditions where it plays a meaningful clinical role. For the infections most people think of when they hear “STD” or “STI,” such as chlamydia, gonorrhea, and syphilis, clindamycin is either unreliable or outright ineffective. The distinction matters, because getting prescribed clindamycin after a gynecological visit does not necessarily mean you have a classic sexually transmitted infection, and assuming it covers one could lead to untreated disease spreading to a partner.

Bacterial Vaginosis Is the Primary Target

Bacterial vaginosis, or BV, is the condition clindamycin is most commonly prescribed for in the context of sexual health. BV happens when the balance of bacteria in the vagina shifts away from protective lactobacilli toward a mix of other organisms. It causes a thin grayish discharge, a fishy odor, and sometimes irritation, though many people with BV have no symptoms at all. Whether BV should be formally classified as a sexually transmitted infection is still debated. It is strongly associated with sexual activity, more common in people with new or multiple partners, and can be shared between sexual partners, but it can also occur in people who have never had sex. Most clinical guidelines treat it as a sexually associated condition rather than a traditional STI.

Clindamycin is one of two first-line treatments for BV, the other being metronidazole. A clinical trial comparing intravaginal clindamycin cream with oral metronidazole found that both performed similarly, with cure or improvement rates around 78 to 83% at one month after treatment.¹ Both drugs also promoted similar restoration of healthy vaginal lactobacilli within about three to four weeks.² The choice between them often comes down to side effects, convenience, and personal preference rather than any large gap in effectiveness.

Pelvic Inflammatory Disease, Usually Combined With Another Antibiotic

Pelvic inflammatory disease is an infection of the uterus, fallopian tubes, or ovaries, usually caused by bacteria that ascend from the vagina or cervix. It can be triggered by chlamydia, gonorrhea, BV-associated bacteria, or a mix of organisms. When PID is serious enough to require hospitalization and intravenous antibiotics, clindamycin paired with gentamicin is one of the standard regimens recommended in clinical guidelines.

A retrospective study found the clindamycin-plus-gentamicin combination to be an effective treatment protocol for PID.³ In a randomized trial comparing this combination to sulbactam/ampicillin, the clindamycin group showed a clinical response rate above 94% and a bacteriological eradication rate of about 97%.⁴ Another trial found comparable cure rates between clindamycin-gentamicin and cefotaxime for complicated PID, including cases involving tubo-ovarian abscesses.⁵

There is an important caveat here. Clindamycin’s role in PID is specifically to cover anaerobic bacteria, which are organisms that thrive without oxygen and are common in deep pelvic infections and abscesses. The gentamicin handles gram-negative bacteria. But if chlamydia is confirmed or suspected as the cause, guidelines recommend adding doxycycline after the initial clindamycin-gentamicin course, because clindamycin alone is not reliable against chlamydia.⁶ So even in PID treatment, clindamycin is doing the anaerobic heavy lifting, not treating the STI organism itself.

Why It Falls Short Against Chlamydia

Clindamycin has some laboratory activity against Chlamydia trachomatis, which has occasionally led to the assumption that it could work as a treatment. In practice, it cannot be counted on. A study of men with chlamydial urethritis found that chlamydia was re-isolated in nearly a third of men who had tested positive before clindamycin treatment, meaning the drug failed to clear the infection in a substantial number of patients.⁷ The researchers concluded that clindamycin cannot be relied upon to eliminate chlamydia.

This is one of the more common points of confusion. If you are being treated with clindamycin for BV or PID and also have chlamydia, the clindamycin is not covering the chlamydia. You will need a separate antibiotic, typically doxycycline or azithromycin, to address it. Assuming the clindamycin will handle everything could leave you with an untreated chlamydial infection that you could pass to a partner or that could progress to more serious complications.

No Meaningful Activity Against Gonorrhea or Syphilis

For gonorrhea, the picture is even bleaker. Laboratory testing of Neisseria gonorrhoeae strains, including those isolated from patients with PID, showed that at least half of isolates required relatively high concentrations of clindamycin to be inhibited, suggesting poor activity.⁸ Gonorrhea treatment relies on ceftriaxone, and there is no scenario in current medicine where clindamycin would be appropriate for it.

Syphilis is similar. An animal study comparing clindamycin to penicillin and erythromycin against Treponema pallidum, the bacterium that causes syphilis, found that even repeated doses of clindamycin reduced bacterial counts only modestly, while penicillin and erythromycin brought counts down dramatically, by more than 300-fold.⁹ Clindamycin is not used for syphilis treatment in humans.

What About Mycoplasma and Ureaplasma?

Mycoplasma hominis and Ureaplasma urealyticum are two organisms increasingly recognized as causes of genital and urinary tract symptoms. They are sexually transmitted and can cause urethritis, cervicitis, and complications in pregnancy. Clindamycin’s effectiveness against them differs sharply depending on which one you are dealing with.

Laboratory testing of strains isolated from pregnant women found that clindamycin was highly active against Mycoplasma hominis, with very low concentrations needed to inhibit growth. Against Ureaplasma urealyticum, however, the concentrations required were much higher, putting clindamycin in the “least active” category for that organism.¹⁰ If you are being treated for a Mycoplasma hominis infection, clindamycin is a reasonable choice. For Ureaplasma, other antibiotics are preferred.

Vaginal Cream, Ovules, or Oral Pills

When clindamycin is prescribed for BV, it comes in several forms, and the differences between them are more meaningful than you might expect. The three main options are vaginal cream (applied with an applicator for seven days), vaginal ovules or suppositories (typically a three-day course), and oral capsules.

The vaginal cream delivers clindamycin directly to where BV lives, with only about 4% of the drug being absorbed into the bloodstream.¹¹ That low absorption makes systemic side effects uncommon. The ovule form, by contrast, had about 30% systemic absorption in the same study, roughly seven times more than the cream. That is still much less than an oral dose, but it is a meaningful difference if you are concerned about side effects. The tradeoff is convenience: a three-day course with an ovule is easier to complete than a seven-day cream regimen, and surveys suggest patients prefer it, largely because of the shorter treatment duration and less messiness.¹²

Newer sustained-release vaginal cream formulations have pushed absorption even lower. A study comparing a single-dose sustained-release cream to the standard cream found that systemic absorption from the sustained-release version was only about 12% of the standard cream’s level.¹³ For people who want the least systemic exposure possible, newer cream formulations offer that, though availability varies by region.

Oral clindamycin is typically reserved for situations where vaginal application is not practical, or when BV is being treated alongside a broader pelvic infection. The oral route comes with a higher risk of gastrointestinal side effects, including the concern about Clostridioides difficile infection discussed below.

Clindamycin for BV During Pregnancy

BV during pregnancy has been linked to preterm birth and late miscarriage, which has prompted research into whether treating it with antibiotics can reduce those risks. A systematic review and meta-analysis found that clindamycin given before 22 weeks of pregnancy was associated with a lower risk of preterm birth before 37 weeks and a reduced risk of late miscarriage.¹⁴ The vaginal preparation was considered safer than oral clindamycin during pregnancy due to its limited systemic absorption.

However, a later randomized controlled trial complicated that picture. It found no evidence that screening for and treating BV in low-risk pregnancies reduced the risk of late miscarriage or very preterm birth, leading the researchers to suggest that antibiotic use for this purpose in low-risk women should be reconsidered.¹⁵ The clindamycin groups in that trial also had more adverse events, including diarrhea and abdominal pain, than the placebo group. Current practice tends to favor treating BV in pregnancy when symptoms are present, but routine screening and treatment for all pregnant women remains controversial.

The C. difficile Concern

Clindamycin has a well-known association with Clostridioides difficile infection, a potentially serious intestinal illness that happens when antibiotics wipe out enough normal gut bacteria to let C. difficile take over. In a large study of over five million delivery hospitalizations, women who received clindamycin had roughly a threefold increased risk of C. difficile infection compared to women given other antibiotics.¹⁶ The absolute risk was still low, at about 0.04% of clindamycin recipients, but the relative increase is worth knowing about, especially for hospitalized patients or anyone who has had C. difficile before.

This risk is substantially lower with vaginal formulations than with oral or intravenous clindamycin, because so little of the drug reaches the gut. If you are being treated for BV with a vaginal cream or ovule, the C. difficile concern is much less relevant than if you are taking clindamycin pills or receiving it through an IV for PID.

BV Recurrence and Whether Treating Partners Helps

One of the most frustrating aspects of BV is its high recurrence rate. Many people find that symptoms return within months of successful treatment, which has fueled a long debate about whether treating male sexual partners could prevent BV from coming back. For years, trials of male partner treatment showed no clear benefit. A randomized trial giving male partners either clindamycin or placebo found no significant difference in women’s BV recurrence rates at three months.¹⁷

That changed with a 2024 trial published in the New England Journal of Medicine, which used a more aggressive approach: male partners received both oral and topical antibiotics simultaneously. In that trial, BV recurrence dropped to 35% in the partner-treatment group compared to 63% in the control group, a large and statistically significant difference.¹⁸ The finding suggests that BV-associated bacteria harbored by male partners play a real role in reinfection, and that earlier trials may have failed because they did not treat partners aggressively enough. A pilot study exploring combined oral and topical treatment for male partners had previously pointed in this direction, noting promising changes in the genital microbiota of couples but calling for larger trials with longer follow-up.¹⁹

This is a rapidly evolving area. If you are dealing with recurrent BV, it is worth discussing concurrent partner treatment with your healthcare provider, as clinical guidelines may update in response to the newer evidence.

How Clindamycin Actually Works

Clindamycin belongs to a class of antibiotics called lincosamides. It works by blocking the machinery bacteria use to build proteins, which stops them from growing and reproducing. At typical doses it slows bacterial growth without necessarily killing the organisms outright. At higher concentrations it can kill bacteria directly.²⁰ This mechanism is especially effective against anaerobic bacteria, which is why clindamycin shines in BV and in the anaerobic component of pelvic infections. It is much less effective against organisms like chlamydia and gonorrhea, which have different cellular structures and growth patterns that make them harder for lincosamides to reach or inhibit.

Understanding this explains the pattern across every condition discussed here. Clindamycin is strong where anaerobes are the problem, adequate against Mycoplasma hominis, partially active against chlamydia but not enough to rely on, and essentially useless against gonorrhea and syphilis. If you are prescribed clindamycin after an STI screening, it almost certainly means the target is BV or anaerobic bacteria in a pelvic infection, not a classic sexually transmitted organism. If you tested positive for chlamydia, gonorrhea, or syphilis, you should confirm with your provider that a separate antibiotic has been prescribed for that specific infection.